a[C-l llMethyl-L-tryptophan (AMT) is an analog of tryptophan used with positron emission tomography for the measurement of serotonin synthesis in humans. Several at tempts have been made to estimate the serotonin synthesis rate from plasma and brain kinetic data of AMT using the same model as that applied for the measurement of the glucose meta bolic rate with 2-deoxyglucose. However, although AMT is similar to 2-deoxyglucose with regard to an irreversible pool of tracer uptake, there are important differences between the two tracers and how the model can be applied. These differences include transport at the blood-brain barrier and the presence of a large unmetabolized pool of AMT, precluding the method from providing the absolute serotonin synthesis rate. Despite this limitation, the unidirectional uptake rate constant (K-Alpha-methyl-L-tryptophan (AMT) is an analog of tryptophan, the precursor of the neurotransmitter seroto nin (5-HT, 5-hydroxytryptamine). For the past decade, Diksic and colleagues performed numerous studies of radiolabeled AMT in rats and dogs with the goal of vali dating AMT as a tracer for the measurement of the rate of sertonin synthesis in vivo in humans with positron emission tomography (PET) (Diksic et aI., 1990(Diksic et aI., , 1991. After the administration of labeled AMT in rats, autora diograms elegantly demonstrated a distribution of high tracer concentration in serotonergic cell bodies in the raphe nuclei. The synthesis of a-methyl-serotonin in Abbreviations used: AMT, a[C-l lIMethyl-L-tryptophan; FDOPA, L-3,4-dihydroxy-6-[F-18Ifluorophenylalanine; 5-HIAA, 5-hydroxyin dole acetic acid; 5-HT, 5-hydroxytryptamine; PET, positron emission tomography.
brain after tracer administration was confirmed by high performance liquid chromatography (Missala and Sourkes, 1988; Diksic et aI., 1990) . The [H-3]a-methyl serotonin synthesized in brain was localized to seroto nergic neurons and nerve terminals by combined autora diography and tryptophan hydroxylase immunocyto chemistry at the electron microscopic level (Cohen et aI., 1995) . Furthermore, [H-3]a-methyl-serotonin present in nerve terminals was released by K+ induced depolariza tion, suggesting that this tracer is stored with the releas able pool of serotonin (Cohen et aI., 1995) . In addition, AMT, unlike tryptophan, was not incorporated into pro tein in significant amounts (Madras and Sourkes, 1965; Diksic et aI., 1990) . These studies strongly suggested that AMT was a suitable tracer for the measurement of sero tonin synthesis in vivo in humans with PET. and Schmall, 1996) , and humans Nishizawa et a!., 1997; Chugani et a!., 1998a) have sug gested that the kinetic behavior of the tracer AMT can be described by a three-compartment model using first order rate constants (schematically represented in Fig. 1 ). The inflow rate constant K1 (mUg per minute) and the outflow rate constant k2 (I1min) both describe the ex change of [C-ll] AMT between vascular space and the cell cytoplasm (transport across the blood-brain barrier, the interstitial space, and the cell membrane), and k3 (l/min) describes the rate of synthesis of a[C-ll ]methyl serotonin. This is essentially the same model described by Sokoloff et a!. (1977) for estimation of the glucose metabolic rate using the tracer [C-14]2-deoxyglucose. Sokoloff exploited the property of 2-deoxyglucose which is irreversibly trapped in brain tissue and measured the unidirectional uptake rate. Similarly, because a-methyl serotonin is not a substrate for the degradative enzyme monoamine oxidase (Missala and Sourkes, 1988) , accu mulation of a-methyl-serotonin occurs in serotonergic terminals. According to the 2-deoxyglucose model, the glucose metabolic rate is equal to the product of the plasma glucose concentration and the K-complex (the K-complex is equal to the term [K1k3]/[k2 + k3]) divided by the "lumped constant" (a term which corrects for differences in transport and metabolism between glucose and 2-deoxyglucose). However, although AMT is similar to 2-deoxyglucose with regard to an irreversible pool of tracer uptake in the third compartment, there are impor tant differences between the two tracers and how the model can be applied.
TRYPTOPHAN AND GLUCOSE
TRANSPORT DIFFER 2-Deoxyglucose competes only with glucose for trans port into the brain by means of the glucose transporter. The plasma concentration of glucose is approximately equal to the Km of the glucose transporter under normal circumstances (for review, see Lund-Andersen, 1979 ). In . The inflow rate constant K, and the outflow rate constant k2 both describe the exchange of [C-11] AMT between vascular space (C p ) and the cell cytoplasm (Cf). Once present in the cytoplasm, [C-11] AMT is converted to [C-11] alpha-methyl serotonin (Cm) by means of an irreversible, 2-step enzymatic process which is characterized by the rate constant k3. The pos itron emission tomography (PET) tissue signal is denoted as CPET and represents a combination of both the Cf and Cm signals. the blood-brain barrier (BBB) is saturated under normal condi tions. Therefore, [C-11] AMT in plasma competes with the sum of all LNAA for transport across the BBB, not only against plasma tryptophan. Because tryptophan constitutes only a small fraction of the LNAA pool (about 5%), even doubling the tryptophan con centration will change the LNAA pool by only 5%, causing a change of the same magnitude in the transport of [C-11] AMT.
contrast, tryptophan accounts for only approximately 5% of the total large neutral amino acid pool (Pardridge, 1977; Smith et a!., 1987) with which the tracer [C-ll] AMT competes at the blood-brain barrier for entry into the brain. Furthermore, the large neutral amino acid transporter is close to saturation under normal circum stances (Oldendorf, 1971; Smith et aI., 1987) . Therefore, even large changes in plasma tryptophan concentration will have little effect on the transport of [C-l1]AMT into the brain. In the example shown in Fig. 2 , a 100% in crease in plasma tryptophan results in only a 5% change in total large neutral amino acid pool with which [C-ll]AMT must compete for brain entry. Thus calcu lating the serotonin synthesis rate by multiplying the K complex for [C-ll]AMT by the plasma-free tryptophan level as proposed by Diksic and colleagues (Diksic et al. 1990 (Diksic et al. , 1991 Nishizawa et aI., 1997) is erroneous.
REGULATORY MECHANISMS OF

HEXOKINASE AND TRYPTOPHAN
HYDROXYLASE DIFFER
The glucose metabolic rate is governed by the needs of the tissue through the tight regulation of hexokinase and is independent of the plasma concentration of glucose under normal physiologic conditions. Therefore, any in crease or decrease in the plasma glucose concentration results in a reciprocal change in the unidirectional uptake rate constant (or K-complex), rendering the value of the K-complex alone useless without global normalization (Fig. 3A) . In contrast, the rate of serotonin synthesis is influenced by changes in plasma tryptophan concentra tion. An increase in plasma tryptophan results in in creased transport into the brain and increased serotonin synthesis rate (Fernstrom and Wurtman, 1971) . Indeed, studies of serotonin synthesis in brainstem slices show that increasing tryptophan concentration does not de crease the activity of tryptophan hydroxylase (Hamon et aI., 1981) . Similarly, studies using the AMT model by Shoaf et al. (1998) in monkeys also demonstrate that plasma tryptophan and plasma-free tryptophan values do not show an inverse relationship to the K-complex for AMT ( Fig. 3B ).
K-COMPLEX OR "SEROTONIN SYNTHESIS
CAPACITY" IS A STABLE TRAIT Shoaf et al. (1998) showed that values for K-complex were highly reproducible in the same animal under the same test-retest conditions, whereas values for plasma tryptophan and free tryptophan were not. These data sug gest that for AMT, the K-complex is a stable parameter characteristic for the individual and thus has meaning independent of the plasma tryptophan or plasma-free tryptophan, values which would be used to calculate the serotonin synthesis rate according to the model as ap plied for glucose metabolism. With regard to stability of the K-complex, the kinetics of AMT can be more cor rectly compared to those of L-3,4-dihydroxy-6-[F-18] fluorophenylalanine (FDOPA). FDOPA is a precursor of dopamine and has been used as a PET tracer to provide an index of dopamine synthesis. Like AMT, FDOPA is transported across the blood-brain barrier by the large neutral amino acid transporter and is metabolized in the brain by an enzyme (aromatic amino acid decarboxylase) which is insensitive to changes in substrate concentra tion. Huang et al. (1991) have shown that in fasted in dividuals the transport rate constant K1 is a very stable parameter (0.031 ± 0.0006), apparently insensitive to dif ferences in plasma amino acid levels present in the fast-
ing state. Furthermore, the K-complex for FDOPA has been shown to be a very stable parameter (Yu et aI., 1993) which is capable of not only discriminating be tween control and patient populations but also of follow ing the progression of disease in the same individual (Vingerhoets et aI., 1996) .
We have suggested that for AMT, the K-complex is a stable parameter which represents, in physiologic terms, the serotonin sythesis capacity of the individual (Chu gani et aI., 1998a), whereas the application of the opera tional equation described above to [C-l1 ] AMT with plasma values of tryptophan or free tryptophan concen tration appears to be incorrect. Because the K-complex is a stable value, changes in plasma-free tryptophan would result in proportional changes in the calculated serotonin synthesis rate if one were to use the glucose model. How ever, previous animal experiments do not support an in crease in the serotonin synthesis rate which is propor tional to the plasma tryptophan or free tryptophan con centrations. For example, a 100% increase in plasma tryptophan concentration resulted in a 50% increase in brain tryptophan and only a 20% increase in brain sero tonin content (Fernstrom and Wurtman, 1971) . Similarly, a two-fold increase in plasma-free tryptophan resulted in a 53% increase in forebrain tryptophan (Bloxam et aI., 1980) .
RANK ORDER OF K-COMPLEX V ALVES
The rank order of regional brain values for K-complex are consistent with the rank order for serotonin content in human brain (Chug ani et aI., 1998a) . Although the high est concentrations of serotonin and various measures of innervation density measured in vitro are localized to serotonergic cell bodies in the brainstem nuclei, the brain stem was not among the regions with high K complex values. This finding is not unexpected, how ever, because of the limits of the spatial resolution of PET technology (reconstructed image in-plane resolution obtained is 5.5 ± 0.35 mm at full-width-at-half maximum and 6.0 ± 0.49 mm in the axial direction) compared to the small size of the nuclei containing the several thousand serotonergic cell bodies located near the midline of the brainstem (Tork, 1990; Tork and Hor nung, 1990) , as well as the problem of partial volume in very small structures (Hoffman et aI., 1979) . The rank order of K-complex values for the remaining brain re gions, however, showed a statistically significant corre lation with the rank order of serotonin content in human brain (Costa and Aprison, 1958; Cochran et aI., 1976; Mackay et aI., 1978; Bucht et aI., 1981) . The highest values for serotonin synthesis capacity were found in putamen, caudate, thalamus, and hippocampus. Among cortical regions, limbic areas such as rectal gyrus, ante rior cingulate gyrus, and transverse temporal gyrus dem-onstrated higher rates of serotonin synthesis than other regions of the cortex.
GENDER DIFFERENCES IN
SEROTONIN SYNTHESIS
Previous studies have shown that there are gender dif ferences in serotonin synthesis in both humans and ani mals, with females having a small but significantly higher serotonin synthesis rate than males. Specifically, reports in female rats compared to male rats showed significantly higher serotonin content (Kato, 1960; Ro sencrans, 1970; Carlsson et aI., 1985) , higher 5-hydroxy tryptophan accumulation after inhibition of aromatic amino acid decarboxylase (Watts and Stanley, 1984; Carlsson et aI., 1985) , as well as higher serotonin accu mulation after monoamine oxidase inhibition (Ro sencrans, 1970; Carlsson et aI., 1985; Carlsson and Carlsson, 1988) . In our studies, values of the K-complex for AMT in humans also showed a small but signifi cantly higher value in women than in men (Chug ani et aI., 1998a) . In contrast, multiplication of the K-complex with the free plasma tryptophan concentration produced the opposite result (Nishizawa et aI., 1997) . They report 50% higher serotonin synthesis rates in males than in females, at odds with studies in the literature.
DEVELOPMENTAL CHANGES IN
SEROTONIN SYNTHESIS
Developmental changes in brain serotonin content and serotonin receptor binding have been demonstrated in nonhuman primates (Goldman-Rakic and Brown, 1982; Lidow et aI., 1991) . There is a rise in serotonin content in cortex beginning before birth reaching a peak at 2 months of age, followed by a slow decline until 3 years of age (Goldman-Rakic and Brown, 1982) . Expression of serotonin receptors showed a similar developmental time course (Lidow et aI., 1991) . In humans, measures of the serotonin metabolite 5-hydroxyindole acetic acid (5-RIAA) in cerebrospinal fluid show higher values in chil dren compared to adults (Seifert et aI., 1980; Redner et aI., 1986) . For nonautistic children, we showed that the K-complex for AMT was >200% of adult values until the age of 5 years and then declined toward adult values. Furthermore, K-complex values declined at an earlier age in girls than in boys (Chugani et aI., 1999) . The earlier decline in the developmental curve for whole brain serotonin synthesis capacity in girls as compared to boys is consistent with earlier onset of puberty in girls (Tanner et aI., 1976) .
K-COMPLEX OR SEROTONIN SYNTHESIS
CAPACITY IS SENSITIVE TO CHANGES IN
BRAIN DISORDERS
There are numerous li�es of evidence suggesting a role of serotonin in autism (for review see Cook and Leventhal, 1996) . In contrast to the developmental pat tern described for nonautistic children above, serotonin synthesis capacity increased gradually between the ages of 2 and 15 years to values 1 '12 times those of normal adult values and showed no gender difference in autistic children (Chugani et aI., 1999) . These data suggest that the developmental process with a period of high brain serotonin synthesis capacity during childhood is dis rupted in autistic children. Furthermore, we have found focal asymmetries of [C-ll ]AMT uptake in frontal cor tex, thalamus, and cerebellum in autistic children (Chu gani et aI., 1997) .
Migraine is another disorder in which serotonin patho physiology has been implicated (for review, see Silber stein, 1994). Measurements of plasma 5-RT and 5-RIAA levels between and during migraine attacks showed low 5-RT and high 5-RIAA levels in plasma between mi graine attacks (Ferrari et aI., 1989) . During migraine headache in patients without aura, the plasma 5-RT was higher and 5-RIAA levels and platelet monoamine deg radative enzyme activities were lower than in controls. Ferrari et aI. hypothesized that 5-RT turnover is en hanced between migraine attacks and is relatively de creased during attacks in patients having migraine with out aura. Our finding of increased brain serotonin syn thesis capacity in migraine patients without aura between attacks is consistent with increased 5-RT turnover and supports this hypothesis (Chugani et aI., 1999) . Shoaf et aI. (1999) assert that AMT is no different from FDOP A and that both tracers are simply measuring amino acid transport. However, the distribution of these tracers is proportional to the serotonergic (AMT, Chu gani et aI., 1998a) or to the dopaminergic (FDOPA, Snow et aI., 1993) innervation. In our human data ob tained from dynamic AMT PET studies, we found that at 60 minutes after tracer injection about 50% of the activ ity was in a "trapped" pool, but we do not have data to show whether this activity represents unchanged AMT or a metabolite (Chugani et aI., 1998a) . Furthermore, we showed that the rank order of regional K-complex values matched that of serotonin content-but the magnitude of the difference among structures was much lower for K complex than for serotonin content. We interpreted this difference to mean that there is a large unmetabolized pool. This interpretation is supported by animal studies by Diksic et aI. (1990) and a recent report by Gharib et aI. (1999) . Thus, we have reported K-complex values which we suggest are an index of serotonin synthesis (or under some circumstances kynurenine pathway metabo lism, see below), but the technique cannot be construed to measure the serotonin synthesis rate. In essence, the serotonin synthesis component of the tracer uptake is superimposed on a large unmetabolized pool of AMT (Fig. 4) . Shoaf et al. (1999) question the unidirectional uptake of AMT into tissue based on kinetic analysis of dynamic AMT PET data. It is extremely difficult to prove or dis prove the existence of unidirectional AMT uptake (i.e., the existence of a metabolic compartment) using dy namic PET and [C-ll] AMT. The problems associated with this task are numerous (Muzik et aI., 1997) . First, the time to reach dynamic equilibrium of AMT is long compared to the physical half-life of the [C-ll] tracer. The best estimates suggest that dynamic equilibrium is reached not earlier than after 80 minutes (Muzik et aI., 1997) , four times the length of the physical half-life of [C-ll] (20 minutes). Data acquired during this equilib rium phase are most important for a reliable estimation of parameters k2 arid k3 characterizing accumulation of tracer into tissue. However, because of the low uptake of tryptophan into brain tissue (about 2%) and the short physical half-life of [C-l1] , for all practical purposes the length of the acquisition period is limited to approxi materly 60 minutes. After this time, the quality of the PET images is highly compromised by the low-count statistics of this tracer. In addition, by this time the nec essary decay-correction magnifies the statistical noise by a factor in the order of 10, making it difficult to estimate the k2 and k3 parameters more reliably. Our previous results comparing a three-compartment model against a two-compartment model applied to the initial 60 minutes of data were inconclusive (Muzik et aI., 1997) . Based strictly on the magnitude of the residuals, the three compartment model configuration did not describe the data significantly better than the two-compartment model configuration. However, visual examination of the 1 2 3 4 5 6 7 8 9 10 11 12
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FIG. 4. The rank order of K-complex values in brain regions correspond to that of serotonin content. However, the serotonin synthesis component of the tracer uptake is superimposed on a large unmetabolized pool of [C-11]AMT (represented by gray shading) wt'lich seems to be irreversibly trapped in brain tissue. residuals indicated that they were not randomly distrib uted around zero but showed sections that were all posi tive, then negative, positive, and negative. These "runs" in the residuals were not observed in the results obtained from the three-compartment model.
Because the identifiability of individual rate constants in the three-compartment model configuration is low, the Patlak graphical approach can be used to determine the K-complex. A requirement for application of the Patlak graphical approach is that the system under study is in dynamic equilibrium, i.e., that the total amount of tracer in the free tissue compartment is constant (Patlak et aI., 1983) . Only when dynamic equilibrium is reached do the differential equations transform into a linear equation and the K-complex can be estimated as the slope of a straight line. In the case of AMT, the linearity of the Patlak plot is compromised by the relatively long time until the system reaches a dynamic equilibrium relative to the time when loss of tracer from the metabolic com partment becomes measurable. It was shown by that even for FDG a k4 has to be taken into account for measurements longer than 120 minutes. Thus, by the time the dynamic equilibrium is reached, loss of tracer becomes measurable and the Patlak-plot might never be truely linear, despite the existence of a conceptually unidirectional compartment. This situation is even further compounded by the low metabolic rate of tryptophan, producing a very small K-complex (slope parameter). Nevertheless, the possible minor nonlinear ity of the Patlak-plot attributable to violation of the dy namic equilibrium requirement has little effect on the rank order of regional values of the K-complex. Results of our compartmental analysis suggest that the amount of time needed to reach dynamic equilibrium is fairly con stant between cortical and subcortical regions, with the exception of the cerebellum Chugani et aI., 1998a) . The reason for the apparently longer half life of the free precursor pool in the cerebellum as com pared with other brain structures is unclear and warrants further investigation. In any case, the curves in the re maining gray matter regions will all "bend" by the same amount, and the rank order of the Patlak slopes will be independent from the time interval from which they were derived.
From all the above it is clear that the presence of an unidirectional compartment for AMT has to be estab lished in animal studies, a work rigorously performed by the early investigators in rodents (Missala and Sourkes, 1988; Diksic et al., 1990; Cohen et aI., 1995; Gharib et aI., 1999) . Shoaf et al. (1999) challenge these previous studies based on high-performance liquid chromatogra phy analyses of brain tissue extracts of [l4C]-labeled tracer from four rhesus monkeys, reporting that only 5% of the radioactivity in midbrain represented a-methyl serotonin at 180 minutes after tracer injection. Their findings are in contrast to those reported in the rat by Diksic et al. (1990) who stated that at 180 minutes postinjection 45% of the radioactivity in dorsal raphe was a-methyl-serotonin, and those of Gharib et al. (1999) who reported that 52% of the radioactivity was a-methyl-serotonin at 180 minutes postinjection. In con trast to the rat studies, Shoaf et al. performed high performance liquid chromatography analysis on extracts from a crude dissection of the midbrain and pons rather than dissecting the raphe nuclei. This methodologic problem, rather than species differences, probably ac counts for the discrepancy between the rat and primate studies.
In summary, we believe that the rat studies demon strate unequivocably the presence of irreversible uptake of AMT. However, these studies also demonstrate that the serotonin synthesis component is a fraction of the irreversible uptake of the tracer (Fig. 5) . Thus, although lacking properties.for measuring the absolute synthesis rate, AMT uptake is useful as an index or capacity for serotonin synthesis.
[C-ll]AMT IS A TRACER OF THE KYNURENINE PATHWAY UNDER SOME
PATHOLOGIC CONDITIONS
In addition to metabolism by tryptophan hydroxylase, tryptophan is metabolized by tryptophan 2,3dioxygenase (Haber et aI., 1993) and indole amine 2,3dioxygenase (Yamazaki et aI., 1985) by means of the kynurenine pathway in the brain. Under normal circum stances, the metabolites of these pathways are between 100-and WOO-fold lower than the concentration of tryp tophan in the brain (Saito et aI., 1993) . In comparison, the sum of the concentrations of serotonin and its me tabolite 5-HIAA is approximately one-fifth the concen tration of tryptophan in brain (Hery et aI., 1977) . There fore, the kynurenine pathways are not expected to con tribute to the accumulation of [C-11] AMT in brain under normal circumstances. However, after ischemic brain in jury or immune activation, induction of indoleamine2,3dioxygenase can result in a lO-fold increase in quinolinic acid (a metabolite of the kynurenine pathway) in brain (Saito et aI., 1993) , and, therefore, this pathway should be considered in the disease state. We have preliminary data that this pathway is important in patients with tu berous sclerosis complex and epilepsy (Chugani et aI., 1998b) .
Our rationale for applying AMT in epilepsy patients was based on evidence implicating serotonergic mecha nisms in epileptogenesis. The levels of 5-HT and 5-HIAA have been reported to be higher in actively spik ing temporal cortex, as compared to nons piking cortex (Louw et aI., 1989; Pintor et aI., 1990) . In addition, Trot tier et al. (1996) -11] AMT across the blood-brain bar rier, free [C-11] AMT in the cytoplasm is either metabolized to [C-11]AM-S-HT or is irreversibly trapped, presumably in a sero tonin synthesis precursor pool. It appears that this irreversibly trapped pool is larger than the metabolic pool. Furthermore, un der pathologic conditions [C-11] AMT can also be metabolized by means of the kynurenine, pathway. Thus, the resulting K-complex represents the combined unidirectional uptake into all three pools.
cal methods that epileptogenic dysplastic tissue is char acterized by serotonergic hyperinnervation in patients with focal cortical dysplasia. However, we have reported preliminary biochemical studies of tissue obtained at sur gery that the increase in [ 1 1 C]AMT uptake in cortical tubers (Chugani et aI., 1998c) does not represent in creased 5-HT synthesis (Chugani et aI., 1998b) . Resected tissues (cortex, an epileptogenic tuber with high AMT uptake and a nonepileptogenic tuber with low uptake) were analyzed for tryptophan hydroxylase activity, 5-HIAA, 5-HT, and quinolinic acid. Cortical tissue and the tuber with low AMT uptake contained measurable amounts of 5-HT, 5-HIAA, and tryptophan, but only tryptophan was detected in the tuber with high AMT uptake. Furthermore, tryptophan hydroxylase activity was very low in the epileptogenic tuber. In contrast, quinolinic acid, a tryptophan metabolite of the kynuren ine pathway, was 5-fold higher in the epileptogenic tuber than in nonepileptogenic tuber. It is pertinent that quino linic acid is a convulsant through its action as an agonist at N-methyl-D-aspartate receptors (Lapin, 1982; Perkins and Stone, 1982) .
CONCLUSION
Based on the studies and issues discussed above, we conclude that AMT is a useful tracer for examination of serotonergic mechanisms, although this tracer cannot be used to measure the absolute serotonin synthesis rate (Fig. 5 ). Furthermore, in certain pathologic states, in creased AMT may represent increased metabolism by means of the kynurenine pathway rather than increased serotonin synthesis. A prime concern of future studies is to determine the role of the pool of AMT which is irre versibly transported but not metabolized for up to 3 hours after tracer injection.
